lncRNA Blog lncRNA Research and Industry News
Long non-coding RNAs (lncRNAs) have emerged as biomarkers and important regulators of tumor development and progression. PANDAR (promoter of CDKN1A antisense DNA damage activated RNA) is a novel long non-coding RNA that acts as a potential biomarker and involves in development of multiple cancers. However, the clinical significance and molecular mechanism of PANDAR in bladder cancer is still unknown. In this study, we aimed to figure out the role of PANDAR in bladder cancer.
The relative expression level of lncRNA PANDAR was determined by Real-Time qPCR in a total of 55 patients with urothelial bladder cancer and in different bladder cancer cell lines. PANDAR expression was inhibited by transfecting PANDAR specific siRNA and enhanced PANDAR expression by transfecting a PANDAR expression vector.
PANDAR was significantly up-regulated in bladder cancer tissues compared with paired-adjacent nontumorous tissues in a cohort of 55 bladder cancer patients. Moreover, increased PANDAR expression was positively correlated with higher histological grade and advanced TNM stage. Further experiments demonstrated that inhibited cell proliferation/migration and induced apoptosis by silencing PANDAR were also observed in bladder cancer cells.
Effects of down-regulation or up-regulation of PANDAR on cell proliferation
Cell proliferation was also determined by Edu assay. Cell proliferation inhibition was observed in bladder cancer 5637 cells (a and d), SW780 cells (b and d) and T24 cells (c and d). Cell proliferation promotion was observed in bladder cancer 5637 cells (e and h), SW780 cells (f and h) and T24 cells (g and h). Data are shown as mean ± SD
These findings demonstrate that PANDAR plays oncogenic roles in bladder cancer and PANDAR may serve as a potential prognostic biomarker and therapeutic target of bladder cancer.
